What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness-Reference-Cited by-同舟云学术

What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness

Published:2019-06-30 Issue:2 Volume:54 Page:153-156
ISSN:2287-979X
Container-title:BLOOD RESEARCH
language:en
Short-container-title:Blood Res

Author:

Sekiguchi Naohiro¹²,Hamano Airi³,Kitagawa Tomoko²,Ito Kenichi¹,Hirano Kazuhiko⁴,Yamada Kazuaki⁴

Affiliation:

1. Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan

2. Clinical Research Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan

3. Pharmaceutical Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan

4. Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://synapse.koreamed.org/pdf/10.5045/br.2019.54.2.153

Reference15 articles.

1. MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

2. Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent

3. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

4. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature;BLOOD RESEARCH;2019-09-30